Login / Signup

Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.

Hyung Soon ParkJoohyuk SohnSeung Il KimSeho ParkHyung Seok ParkSeul Ghi GhoHyun Cheol ChungSoonmyung PaikGun Min Kim
Published in: Breast cancer research and treatment (2017)
Among patients with HER2+ MBC, HR status is a possible predictive biomarker of a durable response to trastuzumab-based therapy.
Keyphrases
  • metastatic breast cancer
  • epidermal growth factor receptor
  • stem cells
  • bone marrow
  • tyrosine kinase